BDTX — Black Diamond Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$2.08
+$0.04 (+1.72%)
Black Diamond Therapeutics Inc (BDTX) is a biotechnology company listed on NASDAQ. It is led by Mark A. Velleca M.D., Ph.D., based in 245 First Street, Cambridge, MA, United States, 02142, with about 21 employees. Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Net income was -$8.5M. BDTX currently screens at market cap $95.7M.
Use this BDTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BDTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BDTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Black Diamond Therapeutics Inc even when a live quote feed is slow.
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
BDTX Key Statistics
Market Cap
$95.69M
Volume
21,106
Previous Close
$2.15
Day Range
$2.19 – $2.23
P/B Ratio
0.91
EPS
-$1.27
Revenue
$0.00
Net Income
-$69.68M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
21
BDTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.68M | -$82.44M | -$91.17M | -$125.60M |
| EPS (Diluted) | -$1.27 | -$1.88 | -$2.52 | -$3.47 |
Total Assets
$122.64M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$36.44M
Operating Cash Flow
-$62.30M
Free Cash Flow
$0.00
Black Diamond Therapeutics Inc Company Information
- CEO, President & Chairman
- Mark A. Velleca M.D., Ph.D.
- Headquarters
- 245 First Street, Cambridge, MA, United States, 02142
- Phone
- 617 252 0848
- IPO / Founded
- 2020-01-30
- Sector
- Healthcare
- Industry
- Biotechnology